Department of Nephrology, Monceau Park International Clinic, Paris, France.
Department of Nephrology, Yale University School of Medicine, New Haven, CT, USA.
Nephrol Dial Transplant. 2017 Jul 1;32(7):1089-1097. doi: 10.1093/ndt/gfw467.
The epidermal growth factor receptor (EGFR) is implicated in various malignancies. The past decade has seen the development and widespread use of EGFR inhibitors for the successful treatment of such cancers. Available EGFR inhibitors include small molecule tyrosine-kinase inhibitors and monoclonal antibodies. Class-related renal adverse events result in dual toxicity including tubular/electrolyte disorders and glomerulopathies. Tubular injury is common and mainly due to monoclonal antibodies while glomerulopathy is rare and related to various anti-EGFR agents. The exact pathogenesis of anti-EGFR agents associated with kidney disorders remains to be elucidated.
表皮生长因子受体（EGFR）与多种恶性肿瘤有关。在过去的十年中，已经开发出并广泛使用 EGFR 抑制剂来成功治疗此类癌症。可用的 EGFR 抑制剂包括小分子酪氨酸激酶抑制剂和单克隆抗体。与类别相关的肾脏不良反应导致双重毒性，包括肾小管/电解质紊乱和肾小球病。肾小管损伤很常见，主要与单克隆抗体有关，而肾小球病很少见，与各种抗 EGFR 药物有关。与肾脏疾病相关的抗 EGFR 药物的确切发病机制仍有待阐明。
